MFG
XBI icon

Merit Financial Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Merit Financial Group’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Sell
1,758
-171
-9% -$23.1K ﹤0.01% 1856
2026
Q1 		$246K Sell
1,929
-276
-13% -$34.5K ﹤0.01% 1780
2025
Q4 		$269K Buy
2,205
+150
+7% +$17.2K ﹤0.01% 1626
2025
Q3 		$206K Sell
2,055
-394
-16% -$35.5K ﹤0.01% 1664
2025
Q2 		$203K Buy
+2,449
New +$195K ﹤0.01% 1556
2024
Q3 		– Sell
-2,317
Closed -$215K – 975
2024
Q2 		$215K Buy
+2,317
New +$208K ﹤0.01% 848
2024
Q1 		– Sell
-2,461
Closed -$220K – 931
2023
Q4 		$220K Sell
2,461
-2,046
-45% -$152K 0.01% 702
2023
Q3 		$329K Sell
4,507
-825
-15% -$65.9K 0.01% 560
2023
Q2 		$444K Sell
5,332
-4,716
-47% -$394K 0.01% 495
2023
Q1 		$766K Buy
10,048
+535
+6% +$44.4K 0.03% 325
2022
Q4 		$790K Buy
9,513
+6,200
+187% +$502K 0.03% 333
2022
Q3 		$263K Sell
3,313
-1,000
-23% -$84.3K 0.01% 467
2022
Q2 		$320K Sell
4,313
-980
-19% -$73.6K 0.01% 436
2022
Q1 		$476K Sell
5,293
-36,836
-87% -$3.4M 0.03% 243
2021
Q4 		$4.72M Sell
42,129
-5,919
-12% -$714K 0.46% 25
2021
Q3 		$6.04M Sell
48,048
-11,632
-19% -$1.5M 0.63% 17
2021
Q2 		$8.08M Buy
59,680
+4,496
+8% +$591K 0.76% 13
2021
Q1 		$7.49M Buy
55,184
+3,100
+6% +$464K 0.78% 10
2020
Q4 		$7.33M Buy
52,084
+4,516
+9% +$578K 0.71% 9
2020
Q3 		$5.3M Buy
47,568
+11,246
+31% +$1.26M 0.48% 13
2020
Q2 		$4.07M Buy
36,322
+22,922
+171% +$2.26M 0.4% 18
2020
Q1 		$1.04M Buy
13,400
+466
+4% +$41.3K 0.12% 75
2019
Q4 		$1.23M Sell
12,934
-225
-2% -$19.5K 0.11% 74
2019
Q3 		$1M Buy
13,159
+7,231
+122% +$601K 0.11% 50
2019
Q2 		$519K Hold
5,928
– – 0.06% 59
2019
Q1 		$536K Buy
+5,928
New +$504K 0.07% 54

Other funds holding XBI

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
AAS
Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return
RFM
Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return
EWM
Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return
LHWM
Lake Hills Wealth Management Austin, Texas $220M AUM 39.11% 1-Year Est. Return
MWA
MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return
PI
Parkside Investments Deerfield, Illinois $902M AUM 32.45% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

Merit Financial Group's XBI Position: Q2 2026 in Review

Merit Financial Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 8.9% in Q2 2026, selling an estimated $23.1K and leaving 1,758 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

Merit Financial Group first reported a position in XBI in Q1 2019 and has held it in 26 quarters since. The position peaked at $8.08M in Q2 2021. 141 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Merit Financial Group held 1,758 shares of State Street SPDR S&P Biotech ETF worth $278K as of Q2 2026.
  • Merit Financial Group sold 171 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $23.1K.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #1856 holding.
  • Merit Financial Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2019 and has held it in 26 quarters since.
  • Merit Financial Group's State Street SPDR S&P Biotech ETF position peaked at $8.08M in Q2 2021.
  • 141 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.